KR20190097094A - 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도 - Google Patents

인간 il-15에 특이적으로 결합하는 항체 및 이의 용도 Download PDF

Info

Publication number
KR20190097094A
KR20190097094A KR1020197019269A KR20197019269A KR20190097094A KR 20190097094 A KR20190097094 A KR 20190097094A KR 1020197019269 A KR1020197019269 A KR 1020197019269A KR 20197019269 A KR20197019269 A KR 20197019269A KR 20190097094 A KR20190097094 A KR 20190097094A
Authority
KR
South Korea
Prior art keywords
seq
ser
antibody
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197019269A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 호세 사이먼 레인
메튜 폴라드
앤소니 제랄드 도일
린 도로시 폴톤
애덤 윌리엄 클라크
Original Assignee
세파론, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세파론, 인코포레이티드 filed Critical 세파론, 인코포레이티드
Priority to KR1020237031493A priority Critical patent/KR102706743B1/ko
Publication of KR20190097094A publication Critical patent/KR20190097094A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
KR1020197019269A 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도 Abandoned KR20190097094A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237031493A KR102706743B1 (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
US62/437,143 2016-12-21
PCT/US2017/067917 WO2018119246A1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031493A Division KR102706743B1 (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20190097094A true KR20190097094A (ko) 2019-08-20

Family

ID=62627610

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237031493A Active KR102706743B1 (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
KR1020197019269A Abandoned KR20190097094A (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020237031493A Active KR102706743B1 (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Country Status (30)

Country Link
US (2) US11267883B2 (enExample)
EP (2) EP4585261A3 (enExample)
JP (2) JP7155126B2 (enExample)
KR (2) KR102706743B1 (enExample)
CN (1) CN110234349B (enExample)
AR (1) AR110414A1 (enExample)
AU (2) AU2017382850B2 (enExample)
BR (1) BR112019012570A8 (enExample)
CA (1) CA3046387A1 (enExample)
CL (1) CL2019001729A1 (enExample)
DK (1) DK3558369T3 (enExample)
EA (1) EA201991514A1 (enExample)
ES (1) ES3026508T3 (enExample)
FI (1) FI3558369T3 (enExample)
HR (1) HRP20250482T1 (enExample)
HU (1) HUE071878T2 (enExample)
IL (1) IL267113B2 (enExample)
LT (1) LT3558369T (enExample)
MA (1) MA47130B1 (enExample)
MD (1) MD3558369T2 (enExample)
MX (2) MX2019007357A (enExample)
PE (1) PE20191497A1 (enExample)
PH (1) PH12019501453A1 (enExample)
PL (1) PL3558369T3 (enExample)
PT (1) PT3558369T (enExample)
RS (1) RS66900B1 (enExample)
SI (1) SI3558369T1 (enExample)
UA (1) UA126284C2 (enExample)
WO (1) WO2018119246A1 (enExample)
ZA (1) ZA201903848B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409139B2 (en) 2013-08-05 2016-08-09 Twist Bioscience Corporation De novo synthesized gene libraries
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
AU2016324296A1 (en) 2015-09-18 2018-04-12 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
CN110248724B (zh) 2016-09-21 2022-11-18 特韦斯特生物科学公司 基于核酸的数据存储
SI3558369T1 (sl) 2016-12-21 2025-06-30 Cephalon Llc Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba
WO2018156792A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
KR102637566B1 (ko) 2017-10-20 2024-02-16 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
CN112041438B (zh) 2018-01-04 2025-05-23 特韦斯特生物科学公司 基于dna的数字信息存储
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113785057A (zh) 2019-02-26 2021-12-10 特韦斯特生物科学公司 用于抗体优化的变异核酸文库
KR20210143766A (ko) 2019-02-26 2021-11-29 트위스트 바이오사이언스 코포레이션 Glp1 수용체에 대한 변이체 핵산 라이브러리
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
JP2022550497A (ja) 2019-06-21 2022-12-02 ツイスト バイオサイエンス コーポレーション バーコードに基づいた核酸配列アセンブリ
AU2020355027A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CA3155629A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
CN115066518A (zh) * 2019-12-09 2022-09-16 特韦斯特生物科学公司 针对腺苷受体的变体核酸文库
CN116391127A (zh) * 2020-10-16 2023-07-04 基因泰克公司 抗切割icaspase底物抗体及其使用方法
EP4281112A4 (en) 2021-01-21 2025-01-15 Twist Bioscience Corporation METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORS
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
MA71681A (fr) 2022-08-04 2025-05-30 Novartis Pharma Ag Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (en) 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
RS20050724A (sr) * 2003-02-26 2007-11-15 Genmab A/S., Humana antitela specifična za interleukin 15(il-15)
TW200619227A (en) * 2004-08-11 2006-06-16 Hoffmann La Roche Mutant interleukin-15-containing compositions and suppression of an immune response
EP1860119B1 (en) 2005-02-28 2011-08-03 Institute for Antibodies Co., Ltd. ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP2602323B1 (en) 2007-06-01 2018-02-28 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP3028565B1 (en) * 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
MX341309B (es) * 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anticuerpos especificos del heterodimero de anti-il-23.
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
JP2014534806A (ja) * 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
CN104203982B (zh) * 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
RU2015140915A (ru) * 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
NZ736026A (en) 2015-03-31 2023-02-24 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
AU2016411388A1 (en) * 2016-06-15 2018-11-08 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
SI3558369T1 (sl) 2016-12-21 2025-06-30 Cephalon Llc Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device

Also Published As

Publication number Publication date
SI3558369T1 (sl) 2025-06-30
IL267113B2 (en) 2024-09-01
PE20191497A1 (es) 2019-10-21
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
LT3558369T (lt) 2025-07-25
IL267113B1 (en) 2024-05-01
EP3558369A1 (en) 2019-10-30
RS66900B1 (sr) 2025-07-31
US20200270339A1 (en) 2020-08-27
MX2019007357A (es) 2019-09-05
JP2020501583A (ja) 2020-01-23
EP3558369A4 (en) 2020-09-09
CN110234349B (zh) 2024-03-22
MX2023014081A (es) 2023-12-06
US20220127352A1 (en) 2022-04-28
PT3558369T (pt) 2025-05-06
AU2017382850B2 (en) 2024-11-21
EP3558369B1 (en) 2025-03-26
US12410247B2 (en) 2025-09-09
CA3046387A1 (en) 2018-06-28
PH12019501453A1 (en) 2020-06-15
BR112019012570A2 (pt) 2019-11-26
ES3026508T3 (en) 2025-06-11
ZA201903848B (en) 2023-02-22
MD3558369T2 (ro) 2025-08-31
JP2022176324A (ja) 2022-11-25
AR110414A1 (es) 2019-03-27
KR20230135691A (ko) 2023-09-25
HRP20250482T1 (hr) 2025-06-20
UA126284C2 (uk) 2022-09-14
EA201991514A1 (ru) 2019-12-30
FI3558369T3 (fi) 2025-05-02
DK3558369T3 (da) 2025-05-19
MA47130B1 (fr) 2025-05-30
IL267113A (en) 2019-08-29
JP7155126B2 (ja) 2022-10-18
PL3558369T3 (pl) 2025-06-23
KR102706743B1 (ko) 2024-09-19
EP4585261A3 (en) 2025-08-13
BR112019012570A8 (pt) 2023-01-24
EP4585261A2 (en) 2025-07-16
AU2025201185A1 (en) 2025-03-13
MA47130A (fr) 2019-10-30
HUE071878T2 (hu) 2025-09-28
US11267883B2 (en) 2022-03-08
WO2018119246A1 (en) 2018-06-28
CN110234349A (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
US12410247B2 (en) Polynucleotides encoding antibodies that specifically bind to human IL-15
JP6938383B2 (ja) イヌインターロイキン４受容体アルファに対する抗体
US9624290B2 (en) Lowered affinity antibodies and methods of making the same
US11673950B2 (en) ILT7 binding molecules and methods of using the same
JP2011057704A (ja) Ｃｄ２０結合分子
KR20100067682A (ko) 항-헵시딘 항체 및 그의 용도
CN105377892A (zh) 抗cd25抗体及其用途
KR20190126769A (ko) 항-il-5 항체
CA3065553A1 (en) Il17a antibodies and antagonists for veterinary use
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
JP2020504744A (ja) 枯渇活性を有するヒト化ｃｘｃｒ３抗体およびその使用方法
TWI814094B (zh) 貓抗體變異體
JP4745242B2 (ja) Ｃｄ２０結合分子
HK40013673A (en) Antibodies that specifically bind to human il-15 and uses thereof
HK40013673B (en) Antibodies that specifically bind to human il-15 and uses thereof
EA040821B1 (ru) Антитела, которые специфически связываются с ил-15, и их применение
BR122024020794A2 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
WO2025083273A1 (en) Binding molecules

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902